State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patients

European Neuropsychopharmacology

Volumn 17, Issue 4, 2007, Pages 257-264

  Ritsner, Michael ^a,b   Gibel, Anatoly ^a   Maayan, Rachel ^c   Ratner, Yael ^a   Ram, Eduard ^c   Modai, Ilan ^a,b   Weizman, Abraham ^c,d  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Anxiety; ; Cortisol; ; Dehydroepiandrosterone sulfate; ; Dehydroepiandrosterone; ; Prospective study; Schizophrenia;

Indexed keywords

CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; HYDROCORTISONE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PRASTERONE; PRASTERONE SULFATE; RISPERIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MENTAL PATIENT; MULTIPLE REGRESSION; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; STATE TRAIT ANXIETY INVENTORY;

ADULT; ANALYSIS OF VARIANCE; ANXIETY; CASE-CONTROL STUDIES; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; HUMANS; HYDROCORTISONE; MALE; PREDICTIVE VALUE OF TESTS; SCHIZOPHRENIA;

EID: 33846402115     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.09.001     Document Type: Article

References (51)

1. Akwa Y., and Baulieu E.E. Dehydroepiandrosterone sulfate and dehydroepiandrosterone: neuroactive neurosteroids. Current Opinion in Endocrinology and Diabetes 7 (2000) 160-167
2. Anderson J.E., O'Donnell B.F., McCarley R.W., and Shenton M.E. Progressive changes in schizophrenia: do they exist and what do they mean?. Restorative Neurology and Neuroscience 12 (1998) 1-10
3. Baulieu E.E., and Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. Journal of Endocrinology 150 (1996) S221-S239
4. Bergeron R., de Montigny C., and Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. Journal of Neuroscience 16 (1996) 193-202
5. Boudarene M., Legros J.J., Boudarene M., Legros J.J., and Timsit-Berthier M. Study of the stress response: role of anxiety, cortisol and DHEA-S. Encephale 28 (2002) 139-146
6. Brophy M.H., Rush A.J., and Crowley G. Cortisol, estradiol, and androgens in acutely ill paranoid schizophrenics. Biological Psychiatry 18 (1983) 583-590
7. Ceskova E., Drybcak P., Hrobar P., Lorenc M., Prochazkova H., and Spacek J. The changes of biological markers and treatment efficacy in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 25 (2001) 323-335
8. Corcoran C., Walker E., Huot R., Mittal V., Tessner K., Kestler L., and Malaspina D. The stress cascade and schizophrenia: etiology and onset. Schizophrenia Bulletin 29 4 (2003) 671-692
9. di Michele F., Caltagirone C., Bonaviri G., Romeo E., and Spalletta G. Plasma, dehydroepiandrosterone levels are strongly increased in schizophrenia. Journal of Psychiatric Research 39 (2005) 267-273
10. First M., Spitzer R.L., Gibbon M., and Williams J.B.W. SCID (DSM-IV) Structured Clinical Interview for Axis I DSM-IV Disorders-Patients Edition (SCID-I.P) (1995), Biometrics Research Department, New York State Psychiatric Institute, New York
11. Glei D.A., Goldman N., Weinstein M., et al. Dehydroepiandrosterone sulfate (DHEAS) and health: does the relationship differ by sex?. Experimental Gerontology 39 (2004) 321-331
12. Goodyer I.M., Herbert J., Altham P.M., Pearson J., Secher S.M., and Shiers H.M. Adrenal secretion during major depression in 8- to 16-year-olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Psychological Medicine 26 (1996) 245-256
13. Goodyer I.M., Park R.J., Netherton C.M., and Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. British Journal of Psychiatry 179 (2001) 243-249
14. Harris D.S., Wolkowitz O.M., and Reus V.I. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. The World Journal of Biological Psychiatry 2 (2001) 99-102
15. Hechter O., Grossman A., and Chatterton Jr. R.T. Relationship of dehydroepiandrosterone and cortisol in disease. Medical Hypotheses 49 (1997) 85-91
16. Hintze J.L. NCSS 6.0. Statistical System for Windows. User's Guide (1998), Number Cruncher Statistical Systems, Kaysville Utah
17. Jansen L.M., Gispen-de Wied C.C., Gademan P.J., De Jonge R.C., van der Linden J.A., and Kahn R.S. Blunted cortisol response to a psychosocial stressor in schizophrenia. Schizophrenia Research 33 (1998) 87-94
18. Johnson M.D., Bebb R.A., and Sirrs S.M. Uses of DHEA in aging and other disease states. Ageing Research Reviews 1 (2002) 29-41
19. Kahl K.G., Bens S., Ziegler K., Rudolf S., Dibbelt L., Kordon A., and Schweiger U. Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biological Psychiatry 59 (2006) 667-671
20. Kaneda Y., Fujii A., and Ohmori T. The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Progress in Neuropsychopharmacol and Biological Psychiatry 26 (2002) 935-938
21. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 (1987) 261-267
22. Kimonides V.G., Spillantini M.G., Sofroniew M.V., Fawcett J.W., and Herbert J. Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience 89 (1999) 429-436
23. Labrie F., Belanger A., Cusan L., Gomez J.L., and Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. Journal of Clinical Endocrinology and Metabolism 82 (1997) 2396-2402
24. Lee J.H., Woo J.I., and Meltzer H.Y. Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatry Research 103 (2001) 157-166
25. Majewska M.D., Demirgoren S., Spivak C.E., and London E.D. The neurosteroid dehydroepiandrosterone sulfate is an antagonist of the GABA-A receptor. Brain Research 526 (1990) 143-146
26. Michael A., Jenaway A., Paykel E.S., and Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biological Psychiatry 48 (2000) 989-995
27. Miyamoto S., LaMantia A.S., Duncan G.E., Sullivan P., Gilmore J.H., and Lieberman J.A. Recent advances in the neurobiology of schizophrenia. Molecular Interventions 3 (2003) 27-39
28. Morley J.E., Kaiser F., Raum W.J., Perry H.M., Flood J.F., Jensen J., Silver A.J., and Roberts E. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 7537-7542
29. Muck-Seler D., Pivac N., Jakovljevic M., and Brzovic Z. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biological Psychiatry 45 (1999) 1433-1439
30. Nachshoni T., Ebert T., Abramovitch Y., Assael-Amir M., Kotler M., Maayan R., Weizman A., and Strous R.D. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophrenia Research 79 (2005) 251-256
31. Nafziger A.N., Bowlin S.J., Jenkins P.L., and Pearson T.A. Longitudinal changes in dehydroepiandrosterone concentrations in men and women. The Journal of Laboratory and Clinical Medicine 131 (1998) 316-323
32. Oades R.D., and Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 19 (1994) 373-385
33. Oertel G.W., Benes P., Schirazi M., Holzmann H., and Hoffmann G. Interaction between dehydroepiandrosterone, cyclic adenosine-3′,5′-monophosphate and glucose-6-phosphate-dehydrogenase in normal and diseased subjects. Experientia 30 (1974) 872-873
34. Orentreich N., Brind J.L., Vogelman J.H., et al. Long-term longitudinal measurements of plasma dehydro-epiandrosterone sulfate in normal men. The Journal of Clinical Endocrinology and Metabolism 75 (1992) 1002-1004
35. Parker N.P., Levin E.R., and Lifrak E.T. Evidence for adrenocortical adaptation to severe illness. Journal of Clinical Endocrinology and Metabolism 5 (1985) 947-952
36. Ritsner M., Maayan R., Gibel A., Strous R.D., Modai I., and Weizman A. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. European Neuropsychopharmacology 14 (2004) 267-273
37. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Biadsy H., Modai I., and Weizman A. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology 30 (2005) 1913-1922
38. Ritsner M., Gibel A., Maayan R., Ratner Y., Ram E., Biadsy H., Modai I., Weizman A., Ritsner M., Gibel A., Ram E., Maayan R., and Weizman A. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. European Neuropsychopharmacology 16 (2006) 137-146
39. Ritsner M.S., Gibel A., Ratner Y., Tsinovoy H., and Strous R.D. Improvement of sustained attention, visual and movement skills, but not clinical symptomatology, following dehydroepiandrosterone augmentation in schizophrenia: a randomized double-blind, placebo-controlled, crossover trial. Journal of Clinical Psychopharmacology 26 (2006) 495-499
40. Sawa A., and Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science 296 (2002) 692-695
41. Shirayama Y., Hashimoto K., Suzuki Y., and Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia. Schizophrenia Research 58 (2002) 69-74
42. Speilberger C.D. Self-Evaluation Questionnaire State Anxiety Inventory (STAI Form Y-1) STAIP-AD Test Form Y (1977), Mind Garden Inc.
43. Strous R.D., Maayan R., Lapidus R., et al. Value of dehydroepiandrosterone (DHEA) augmentation in the management of negative symptoms in schizophrenia. Archives of General Psychiatry 60 (2003) 133-141
44. Strous R.D., Maayan R., Lapidus R., Goredetsky L., Zeldich E., Kotler M., and Weizman A. Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophrenia Research 71 (2004) 427-434
45. Strous R.D., Maayan R., Kotler M., and Weizman A. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clinical Neuropharmacology 28 6 (2005) 265-269
46. Tourney G., and Hatfield L. Plasma androgens in male schizophrenics. Archives of General Psychiatry 27 (1972) 753-755
47. Wen S., Dong K., Onolfo J.P., and Vincens M. Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex. European Journal of Pharmacology 430 (2001) 373-374
48. White L., Harvey P.D., Opler L., and Lindenmayer J.P. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study group. Psychopathology 30 (1997) 263-274
49. Wolf O.T., and Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Research. Brain Research Review 30 (1999) 264-288
50. Young A.H., Gallagher P., and Porter R.J. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. American Journal of Psychiatry 59 (2002) 1237-1239
51. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., and Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30 (2005) 1532-1538